Impact of neoadjuvant immunotherapy on postoperative cardiac adverse events in NSCLC: insights from a bidirectional cohort

Key Points

• Postoperative cardiac adverse events did not increase with neoadjuvant immunotherapy compared to neoadjuvant chemotherapy.
• Significant risk factors identified include hypertension and pericardial window creation for cardiac adverse events.
• Bidirectional cohort analysis across lung cancer surgeries evaluated cardiac safety outcomes post-immunotherapy.
• Findings support using neoadjuvant immunotherapy safely during lung cancer operations, warranting further investigation.